How should prostacyclin (e.g., epoprostenol, iloprost) be used—including dosing, monitoring, contraindications, and alternatives—in a patient with severe peripheral vascular disease (critical limb‑ischemia or disabling claudication) who is not a candidate for revascularisation?

Prostacyclin Use in Severe Peripheral Vascular Disease

For patients with critical limb ischemia who cannot undergo revascularization, intravenous iloprost or PGE-1 administered for 7–28 days may be considered to reduce rest pain and promote ulcer healing, though benefit is limited to a minority of patients and does not reduce amputation or mortality risk. 1

Clinical Efficacy and Limitations

Parenteral prostacyclin therapy carries a Class IIb recommendation (Level of Evidence: A), meaning it may be considered but efficacy is uncertain and limited. 1 The largest trial (1,560 patients) demonstrated only marginal improvement in pain and ulcer healing at 6 months, with no significant reduction in amputation or death. 1

• The European Society of Cardiology identifies iloprost as "the only pharmacological agent so far convincingly shown to have a positive influence on prognosis," reporting 65% of treated patients remained alive with both legs intact at 6 months versus 45% with placebo. 1
• The American College of Chest Physicians confirms prostanoids improve rest pain (77 more patients per 1,000 treated) and ulcer healing (136 more per 1,000) but do not prevent amputation or reduce mortality. 1

Dosing Protocols

Iloprost: 0.5–2 ng/kg/min intravenously over 6 hours daily for 7–28 days (most commonly 14–21 days). 1

PGE-1 (alprostadil): 60–80 micrograms over 2–4 hours daily for 7–28 days. 1

• Dose titration should target headache and flushing as endpoints, as higher doses cause gastrointestinal distress and hypotension. 2
• Repeated cycles every 6–12 months may be considered in responders to maintain benefit. 3

Monitoring Requirements

Before initiating therapy:

• Confirm critical limb ischemia with ankle-brachial index <0.5 or ankle pressure <50 mmHg. 1
• Document rest pain, ulcer size, and tissue loss with photography.
• Measure transcutaneous oxygen tension (TcpO₂) and carbon dioxide (TcpCO₂); elevated TcpCO₂ >58 mmHg predicts poor response and higher mortality risk. 3

During infusion:

• Monitor blood pressure hourly during the first infusion; hypotension is dose-limiting. 2
• Assess for headache, flushing, nausea, vomiting, and diarrhea (occur in 75% of patients). 1
• Paradoxically, coagulation may be enhanced during infusion despite theoretical antiplatelet effects, creating thromboembolism risk. 4

Post-treatment:

• Reassess pain scores, ulcer healing, and need for amputation at 6 months. 1
• Response rate is approximately 40–60% for pain relief and ulcer healing. 2

Absolute Contraindications

Oral iloprost carries a Class III recommendation (should not be used) as it does not reduce amputation or death. 1

• Conditions with high bleeding risk (active hemorrhage, recent stroke, uncontrolled hypertension). 2
• Severe heart failure or unstable coronary syndromes (vasodilation may worsen hemodynamics). 2
• Pregnancy and lactation. 2

Critical Management Algorithm

1. Confirm revascularization is truly impossible via duplex ultrasound and angiography; if anatomically feasible, revascularization (bypass or angioplasty) should always be attempted first. 1

2. Initiate or continue antiplatelet therapy: Aspirin 75–100 mg daily or clopidogrel 75 mg daily must be maintained throughout prostacyclin treatment. 1, 5

3. Consider prostacyclin only if:

   • Rest pain is severe and refractory to analgesics
   • Ischemic ulcers are present
   • Patient accepts high adverse event rate (75%) for modest symptom benefit without mortality/amputation reduction 1

4. Administer intravenous iloprost 0.5–2 ng/kg/min over 6 hours daily for 14–21 days, titrating to headache/flushing. 1

5. Reassess at 6 months: If pain improved or ulcers healing, consider repeat cycles every 6–12 months; if no response, discontinue. 3

Alternative and Adjunctive Therapies

Cilostazol is NOT indicated for critical limb ischemia—it is approved only for intermittent claudication and has not been adequately studied in CLI. 1

Pentoxifylline carries a Class III recommendation (not useful) for CLI and should not be used. 1, 6

Angiogenic growth factors remain investigational (Class IIb) and should only be used in clinical trials. 1

Meticulous wound care by specialized clinics is essential, as many amputations occur from inadequate conservative management. 1

Common Pitfalls

• Assuming prostacyclins prevent amputation: They do not reduce major amputation or mortality rates despite improving symptoms. 1
• Using oral iloprost: This formulation is ineffective and should never be prescribed. 1
• Overlooking revascularization options: Even complex anatomy may be amenable to hybrid procedures; prostacyclins are only for truly non-revascularizable patients. 1
• Ignoring thromboembolism risk: Despite theoretical antiplatelet effects, coagulation may paradoxically increase during infusion. 4
• Expecting universal benefit: Only 40–60% of patients respond, and predictors of non-response (elevated TcpCO₂ >58 mmHg) should guide patient selection. 2, 3